Antiviral effects of three novel derivatives of adefovir on the replication of hepatitis B virus

Medicinal Chemistry Research

Volumn 21, Issue 7, 2012, Pages 1179-1187

  Wu, Di ^a,b   Niu, Jun Qi ^a   Ding, Yan Hua ^a   Wu, Xin Yu ^a   Zhong, Bo Hua ^c   Feng, Xiang Wei ^a  

^a JILIN UNIVERSITY   (China)

^b Tumor Hospital of Jilin Province   (China)

^c BEIJING INSTITUTE OF MICROBIOLOGY AND EPIDEMIOLOGY   (China)

Author keywords

Antiviral drugs; Ducks; Hepatitis B virus; Nucleoside tide analogs

Indexed keywords

2 AMINO 6 (3 FLUORO 4 METHOXYLPHENYLTHIO) 9 [2 (PHOSPHONOMETHOXY)ETHYL]PURINE BIS(2,2,2 TRIFLUOROETHYL)ESTER; 2 AMINO 6 (4 METHYLTHIOPHENYLTHIO) 9 [2 (PHOSPHONOMETHOXY) ETHYL]PURINE BIS(2,2,2 TRIFLUOROETHYL)ESTER; 2 AMINO 6 (DIHYDROBENZOFURANYLTHIO) 9 [2 (PHOSPHONOMETHOXY)ETHYL]PURINE BIS(2,2,2 TRIFLUOROETHYL)ESTER; ADEFOVIR; ADEFOVIR DIPIVOXIL; MITOCHONDRIAL DNA; UNCLASSIFIED DRUG; VIRUS DNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIVIRAL ACTIVITY; ARTICLE; CELL PROLIFERATION; CELL STRAIN HEPG2; CELL SURVIVAL; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFECT; DRUG MEGADOSE; DRUG STRUCTURE; DUCK; FATTY LIVER; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; HUMAN CELL; LIVER WEIGHT; NONHUMAN; REAL TIME POLYMERASE CHAIN REACTION; SOUTHERN BLOTTING; VIRUS REPLICATION;

EID: 84861878655     PISSN: 10542523     EISSN: 15548120     Source Type: Journal    
DOI: 10.1007/s00044-011-9616-2     Document Type: Article

References (30)

1. Baek HJ, Lim SC, Kitisin K, Jogunoori W, Tang Y, Marshall MB, Mishra B, Kim TH, Cho KH, Kim SS, Mishra L (2008) Hepatocellular cancer arises from loss of transforming growth factor beta signaling adaptor protein embryonic liver fodrin through abnormal angiogenesis. Hepatology 48:1128-1137
2. Chan C, Abu-Raddad E, Golor G, Watanabe H, Sasaki A, Yeo KP, Soon D, Sinha VP, Flanagan SD, He MM, Wise SD (2005) Clinical pharmacokinetics of alamifovir and its metabolites. Antimicrob Agents Chemother 49:1813-1822
3. Chang TT, Lai CL (2006) Hepatitis B virus with primary resistance to adefovir. N Engl J Med 355:322-323 (author reply 323)
4. Chen CH, Cheng YC (1989) Delayed cytotoxicity and selective loss of mitochondrial DNA in cells treated with the anti-human immunodeficiency virus compound 2′,3′-dideoxycytidine. J Biol Chem 264:11934-11937
5. Chevallier M, Guerret S, Chossegros P, Gerard F, Grimaud JA (1994) A histological semiquantitative scoring system for evaluation of hepatic fibrosis in needle liver biopsy specimens: comparison with morphometric studies. Hepatology 20:349-355
6. Cui L, Yoon S, Schinazi RF, Sommadossi JP (1995) Cellular and molecular events leading to mitochondrial toxicity of 1-(2-deoxy-2-fluoro-1-beta-D- arabinofuranosyl)-5-iodouracil in human liver cells. J Clin Invest 95:555-563
7. Delaney WEt, Edwards R, Colledge D, Shaw T, Furman P, Painter G, Locarnini S (2002) Phenylpropenamide derivatives AT-61 and AT-130 inhibit replication of wild-type and lamivudine-resistant strains of hepatitis B virus in vitro. Antimicrob Agents Chemother 46:3057-3060
8. Dienstag JL (2008) Hepatitis B virus infection. N Engl J Med 359:1486-1500
9. Dusheiko G, Antonakopoulos N (2008) Current treatment of hepatitis B. Gut 57:105-124
10. Fan YF, Lu CC, Chen WC, Yao WJ, Wang HC, Chang TT, Lei HY, Shiau AL, Su IJ (2001) Prevalence and significance of hepatitis B virus (HBV) pre-S mutants in serum and liver at different replicative stages of chronic HBV infection. Hepatology 33: 277-286
11. Feld JJ, Colledge D, Sozzi V, Edwards R, Littlejohn M, Locarnini SA (2007) The phenylpropenamide derivative AT-130 blocks HBV replication at the level of viral RNA packaging. Antiviral Res 76:168-177
12. Funk A, Mhamdi M, Hohenberg H, Heeren J, Reimer R, Lambert C, Prange R, Sirma H (2008) Duck hepatitis B virus requires cholesterol for endosomal escape during virus entry. J Virol 82:10532-10542
13. Gaillard RK, Barnard J, Lopez V, Hodges P, Bourne E, Johnson L, Allen MI, Condreay P, Miller WH, Condreay LD (2002) Kinetic analysis of wild-type and YMDD mutant hepatitis B virus polymerases and effects of deoxyribonucleotide concentrations on polymerase activity. Antimicrob Agents Chemother 46:1005-1013
14. Girard FC, Ottink OM, Ampt KA, Tessari M, Wijmenga SS (2007) Thermodynamics and NMR studies on duck, heron and human HBV encapsidation signals. Nucleic Acids Res 35:2800-2811
15. Gordon M (1996) Severe toxicity of fialuridine (FIAU). N Engl J Med 334:1136-1137 (author reply 1137-1138)
16. Kamiya N, Kubota A, Iwase Y, Sekiya K, Ubasawa M, Yuasa S (2002) Antiviral activities of MCC-478, a novel and specific inhibitor of hepatitis B virus. Antimicrob Agents Chemother 46:2872-2877
17. Lai CL, Yuen MF (2008) Chronic hepatitis B-new goals, new treatment. N Engl J Med 359:2488-2491
18. Lai CL, Gane E, Liaw YF, Hsu CW, Thongsawat S, Wang Y, Chen Y, Heathcote EJ, Rasenack J, Bzowej N, Naoumov NV, Di Bisceglie AM, Zeuzem S, Moon YM, Goodman Z, Chao G, Constance BF, Brown NA (2007) Telbivudine versus lamivudine in patients with chronic hepatitis B. N Engl J Med 357:2576-2588
19. Lok AS (2005) The maze of treatments for hepatitis B. N Engl J Med 352:2743-2746
20. Ono-Nita SK, Kato N, Shiratori Y, Carrilho FJ, Omata M (2002) Novel nucleoside analogue MCC-478 (LY582563) is effective against wild-type or lamivudine-resistant hepatitis B virus. Antimicrob Agents Chemother 46:2602-2605
21. Opii WO, Sultana R, Abdul HM, Ansari MA, Nath A, Butterfield DA (2007) Oxidative stress and toxicity induced by the nucleoside reverse transcriptase inhibitor (NRTI)-2′,3′-dideoxycytidine (ddC): relevance to HIV-dementia. Exp Neurol 204:29-38
22. Prince AM (1996) Severe toxicity of fialuridine (FIAU). N Engl J Med 334:1136 (author reply 1137-1138)
23. Quan DJ, Peters MG (2004) Antiviral therapy: nucleotide and nucleoside analogs. Clin Liver Dis 8:371-385
24. Schultz U, Grgacic E, Nassal M (2004) Duck hepatitis B virus: an invaluable model system for HBV infection. Adv Virus Res 63:1-70
25. Sekiya K, Takashima H, Ueda N, Kamiya N, Yuasa S, Fujimura Y, Ubasawa M (2002) 2-Amino-6-arylthio-9-[2-(phosphonomethoxy) ethyl] purine bis(2,2,2-trifluoroethyl) esters as novel HBVspecific antiviral reagents. J Med Chem 45:3138-3142
26. Soon DK, Lowe SL, Teng CH, Yeo KP, McGill J, Wise SD (2004) Safety and efficacy of alamifovir in patients with chronic hepatitis B virus infection. J Hepatol 41:852-858
27. Wang JQ, Fei X, Gardner TA, Hutchins GD, Zheng QH (2005) Synthesis of 2-amino-6-(4-[11C]methoxyphenylthio)-9-[2-(phosphonomethoxy) ethyl] purine bis(2,2,2-trifluoroethyl) ester as a novel potential PET gene reporter probe for HBV and HSV-tk in cancers. Bioorg Med Chem 13:549-556
28. Wu LL, Yang XB, Huang ZM, Liu HZ, Wu GX (2007) In vivo and in vitro antiviral activity of hyperoside extracted from Abelmoschus manihot (L) medik. Acta Pharmacol Sin 28:404-409
29. Yamada H, Suryanarayanan R (2007) X-ray powder diffractometry of intact film coated tablets-an approach to monitor the physical form of the active pharmaceutical ingredient during processing and storage. J Pharm Sci 96:2029-2036
30. Yuen MF, Tanaka Y, Shinkai N, Poon RT, But DY, Fong DY, Fung J, Wong DK, Yuen JC, Mizokami M, Lai CL (2008) Risk for hepatocellular carcinoma with respect to hepatitis B virus genotypes B/C, specific mutations of enhancer II/core promoter/precore regions and HBV DNA levels. Gut 57:98-102